R&D News | pharmaphorum

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

Rendering of the new Biomedical Research hub in Campus Point, San Diego.

Novartis breaks ground on San Diego biomedical R&D site

Novartis has started construction of a $1.1bn biomedical research centre in San Diego that will serve as the hub for its R&D operations.

News

Lilly strikes $8.8bn-plus alliance with China's Innovent

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

Kailera, Hengrui stake claim to oral weight loss category

Takeda signs $1.7bn AI alliance with Iambic

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

Data builds on Roche's dominance in primary progressive MS

Novartis breaks ground on San Diego biomedical R&D site

Lilly strikes $8.8bn-plus alliance with China's Innovent

UK offers meningitis jab to young people after outbreak

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks